After diagnosis of lung adenocarcinoma, if it is necessary to use targeted drugs or immune drugs, it is usually necessary to do genetic test and immune test. Lung adenocarcinoma patients who need to use targeted drugs or immune drugs after diagnosis need to do genetic test and immune test, so that they can choose appropriate drugs to control lung adenocarcinoma according to the results of the examination. At present, the conventional genes that need to be detected generally include EGFR, ALK, ROS1, etc., and the immune test mainly refers to the examination of the expression status of PDL1. For early stage lung adenocarcinoma patients who are diagnosed and do not have high-risk factors for recurrence and metastasis, they only need to undergo radical surgery, and generally do not need to undergo genetic and immune tests. It is recommended that patients choose the testing method and medication according to the doctor’s instruction, and do not use medication blindly.